Home > Result Summaries: Compounds > topotecan Result Summaries: topotecan GSKStudy ID Phase Title Summary (Download) 100414 phase 2 An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects with Recurrent or Persistent Endometrial Cancer (0 citation(s)) 103369 Phase 3 A randomized phase III study of cisplatin versus cisplatin plus topotecan versus methotrexate/vinblastine/doxorubicin/cisplatin (MVAC) in stage IVB, recurrent or persistent carcinoma of the cervix. (2 citation(s)) 104864/005 Phase 1 Phase I study of topotecan (3 citation(s)) 104864/010 Phase 1 An Open Phase I Study to Determine the Maximal Tolerated Dose of Topotecan HCl Administered Intravenously as a Single Dose Every 21 Days in Patients with Solid Tumors Refractory to All Known Forms of Effective Therapy (1 citation(s)) 104864/012 Phase 2 An Open Phase II Study To Evaluate The Efficacy And Toxicity Of Topotecan Administered Intravenously As Five Daily Infusions Every 21 Days To Women With Advanced Epithelial Ovarian Carcinoma (2 citation(s)) 104864/014 Phase 2 A phase II trial with topotecan 1.5 mg/m2/day for five consecutive days every 21 days in sensitive and refractory subjects with small cell lung cancer (SCLC). (3 citation(s)) 104864/015 Phase 2 An Open Phase II Study to Evaluate the Efficacy and Toxicity of Topotecan Administered Intravenously as Five Daily Infusions Every 21 Days to Patients with Advanced Non-Small Cell Lung Cancer. (3 citation(s)) 104864/017 Phase 1 A Phase I Study of Topotecan HCl Administered on a Daily Times Five Schedule with a Single Infusion of Cisplatin every Three Weeks to Patients with Advanced Non-small Cell Lung Carcinoma. (2 citation(s)) 104864/032 Phase 4 An open label evaluation of topotecan administered intravenously as five daily 30 minute infusions every 21 days to patients with ovarian tumours refractory to other therapies (5 citation(s)) 104864/033 Phase 2 An open, multicenter, Phase II study of intravenous topotecan, given as five daily doses every 21 days, in advanced epithelial ovarian cancer to patients who have failed prior chemotherapy containing paclitaxel and cisplatin or carboplatin (1 citation(s)) 104864/034 Phase 2 An open, multicentre, Phase II study of intravenous topotecan, given as 5 daily doses every 21 days, in advanced epithelial ovarian cancer (3 citation(s)) 104864/039 Phase 3 An Open-Label, Multicenter, Randomized, Phase III Study of Topotecan HCl as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) Versus Taxol. (Administered as a Three-Hour Infusion Every 21 Days) in Women With Advanced Epithelial Ovarian Carcinoma (10 citation(s)) 104864/047 Phase 1 Single-dose Oral Bioavailability and Pharmacokinetics of Topotecan (1 citation(s)) 104864/048 Phase 1 A phase I study to determine the effect of food co-administration on the pharmacokinetics of oral topotecan and to determine the absolute bioavailability of oral topotecan in subjects with malignant solid tumours (1 citation(s)) 104864/049 phase 1 A Phase I Study to Determine the Maximum Tolerated Dose of Topotecan Following Oral Administration over 5, 10 or 21 Days in Patients with Malignant Solid Tumors (3 citation(s)) 104864/051 Phase 2 An Open, Non-Comparative, Phase II Study of Topotecan Given as a Continuous 21-Day Infusion Every 28 days, to Women with Advanced Epithelial Ovarian Cancer who have failed One Prior Chemotherapy Regimen Containing Cisplatin or Carboplatin (6 citation(s)) 104864/053 Phase 2 An Open-Label, Multicenter, Non-Comparative Study of Topotecan as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) in Patients with Small Cell Lung Cancer (3 citation(s)) 104864/057 Phase 2 An Open-Label, Non-Comparative, Phase II Study of Topotecan as Single Agent, First-Line Therapy Administered as a Continuous 21-Day Infusion Every 28 Days to Patients with Stage IIIB and IV Non-Small Cell Lung Cancer. (2 citation(s)) 104864/059 Phase 2 An Open-label, Non-Comparative, Phase II Study of Topotecan as Single Agent, Second-Line Therapy Administered as a Continuous 21-Day Infusion Every 28 Days to Patients with Relapsed or Refractory Small Cell Lung Cancer (9 citation(s)) 104864/065 Phase 2 An open-label multicentre, randomised, phase II comparator study of oral topotecan versus intravenous topotecan for second-line therapy in sensitive patients with small cell lung cancer (1 citation(s)) 104864/067/080 Phase 3 An Open-Label, Multicenter, Randomized, Phase III, Comparative Study of Topotecan, as Single Agent, Second-Line Therapy Administered Intravenously or Orally as Five Daily Doses Every 21 Days in Women with Advanced Ovarian Cancer (1 citation(s)) 104864/078 Phase 2 An Open-Label, Multicenter Study of Single Agent Oral Topotecan Daily Times Five Every 21 Days For First-Line Treatment in Patients with Extensive SCLC Eligible for Oral Therapy (3 citation(s)) 104864/090 Phase 3 An Open Label, Multicenter, Randomized, Phase III Study of Hycamtin (Topotecan) as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) Versus Second-Line Cyclophosphamide, Doxorubicin and Vincristine (CAV) in Patients with SCLC Who Have Relapsed At Le ... (7 citation(s)) 104864/092 Phase 2 Phase II trial with topotecan in patients with small cell lung cancer. (4 citation(s)) 104864/094 Phase 2 EORTC 08957: A phase II trial of Topotecan in combination with Cisplatin as second line treatment in small cell lung cancer (SCLC) (1 citation(s)) 104864/096 Phase 3 An open-label, multicentre, randomised, phase III study of topotecan plus cisplatin versus paclitaxel plus cisplatin for the first-line treatment of patients with advanced ovarian carcinoma. (1 citation(s)) 104864/097 Phase 1 Phase I Study of Topotecan in Cancer Patients with Hepatic or Renal Dysfunction. (2 citation(s)) 104864/100 Phase 1 A phase I study to determine the maximum tolerated doses of paclitaxel, cisplatin and topotecan (PTC) administered intravenously every 21 days as first line therapy in patients with advanced (stage III and IV) ovarian carcinoma. (2 citation(s)) 104864/101 Phase 1 A phase I study to determine the maximally tolerated dose (MTD) and sequence dependent effects of topotecan administered orally once per day for five days with a single intravenous (iv) dose of cisplatin, repeated every three weeks to subjects with malignant tumour. (5 citation(s)) 104864/111 Phase 2 An Open, Comparative, Phase II Study of Immediate Versus Delayed Treatment with Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients with AIDS-Related Progressive Multifocal Leukoencephalopathy. (1 citation(s)) 104864/111127 phase 2 An open-label, multicenter, non-comparative, Phase II study of oral topotecan in combination with bevacizumab for second-line treatment in subjects with relapsed small-cell Lung Cancer (SCLC) (1 citation(s)) 104864/118 Phase 1 An open-label, two period, cross over study to compare the bioavailability of a single dose of oral topotecan in the presence or absence of ranitidine (1 citation(s)) 104864/151 Phase 2 An Open-Label, Non-Comparative, Multicenter Phase II Study of Oral Topotecan as a Single Agent, Second Line Therapy Administered for Five Days in Patients with Advanced Ovarian Cancer (2 citation(s)) 104864/152 Phase 2 A Phase II study to determine the efficacy and safety of oral topotecan given once daily for 5 days with a single intravenous dose of cisplatin on Day 5 repeated every 21 days in patients with advanced non-small cell lung cancer (0 citation(s)) 104864/178 Phase 1 A Phase I study to assess the safety and tolerability of Hycamtin administered sequentially to patients with cancer of the ovary who have received carboplatin and Taxol treatment. (1 citation(s)) 104864/181 Phase 2 Phase II Study of Topotecan in Patients with Extensive Small Cell Lung Cancer (2 citation(s)) 104864/191 Phase 1 Phase I study with Hycamtin (topotecan) and simultaneous radiation in subjects with non-small cell lung cancer (NSCLC) stage IIIb. (0 citation(s)) 104864/201 Phase 3 A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS (1 citation(s)) 104864/203 Phase 2 A phase II study to determine the efficacy and safety of 2.3mg/m2 oral topotecan daily for 5 days every 21 days in patients with advanced breast cancer (1 citation(s)) 104864/204 Phase 2 A Phase II study to determine the efficacy and safety of 2.3 mg/m2 oral topotecan daily for 5 days every 21 days in patients with advanced non-small cell lung cancer (1 citation(s)) 104864/213 Phase 2 An Open-label Evaluation of Topotecan Administered Intravenously as Five Daily 30 Minute Infusions every 21 days to Patients with Ovarian Tumors Refractory to Other Therapies. (0 citation(s)) 104864/230 Phase 1 A study to determine the balance/excretion and pharmacokinetics of SKF-104864 given as oral (2.3 mg/m2) or intravenous (iv) (1.5 mg/m2) doses once daily for 5 days to patients with malignant solid tumours (1 citation(s)) 104864/234 Phase 2 Phase II Trial of Topotecan Combined With Cisplatin in Persistent or Recurrent Squamous and Non-squamous Cervical Cancer (3 citation(s)) 104864/250 Phase 1/2 Phase I/II study of oral topotecan and intravenous paclitaxel in patients with advanced non-small cell lung cancer (phases I and II) and other advanced solid tumors (phase I only) (3 citation(s)) 104864/251 Phase 2 A phase II study to determine the efficacy and safety of topotecan administered intravenously daily for 5 days with a single intravenous dose of carboplatin on Day 1 repeated every 21 days in patients with advanced non-small cell lung cancer (2 citation(s)) 104864/271 Phase 1/2 Phase I/II trial of oral topotecan and oral etoposide in untreated extensive disease small cell lung carcinoma (0 citation(s)) 104864/272 Phase 1 Etoposide, Topotecan and Paclitaxel, “Etopotax” in Patients with Refractory Malignancy: A Phase I Trial (1 citation(s)) 104864/373 Phase 2 A Phase I/II Study to Determine the Maximum Tolerated Doses of Oral Topotecan, Carboplatin and Paclitaxel Administered every 21 Days to Patients with Epithelial Ovarian Cancer Stages IIb, IIc, III and IV (1 citation(s)) 104864/386 Phase 2 An open-label, multicenter, randomized, phase II study of 5-day oral topotecan vs. 21-day oral topotecan vs. CPT-11 (Irinotecan) for second-line therapy in patients with colorectal carcinoma (0 citation(s)) 104864/396 Phase 3 An open-label, multicentre, randomised, phase III comparator study of oral topotecan versus intravenous topotecan for second-line therapy in patients with SCLC who have relapsed greater than or equal to 90 days after completion of first-line therapy (1 citation(s)) 104864/405 Phase 2 An Open Label, Multicenter, Randomized, Phase II Study of Topotecan and Paclitaxel vs. Etoposide/Cisplatin as First Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer (4 citation(s)) 104864/410 Phase 2 A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer (4 citation(s)) 104864/435 Phase 2 A Phase II Study of Topotecan and Paclitaxel as First-Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer (1 citation(s)) 104864/438 Phase 1 Phase I Study of Oral Topotecan in Patients with Hematological Myeloid Malignancies (0 citation(s)) 104864/478 phase 3 An Open-Label, Multicentre, Randomised, Phase III Comparator Study of Active Symptom Control alone or in Combination with Oral Topotecan in Patients with Relapsed Resistant SCLC (1 citation(s)) 104864/502 Phase 2 An Open-Label, Multicenter, Randomized, Phase II Study of Oral Topotecan Daily x 5 Days vs. Oral Topotecan 5 Days On, 2 Days Off for 3 Weeks for Second-Line Treatment in Patients with Recurrent, Locally Advanced or Metastatic Cervical Cancer (0 citation(s)) 104864/507 Phase 1 Phase I Study of the Effect of Oral Cyclosporin A on the Pharmacokinetics of Oral Topotecan (0 citation(s)) 104864/511 Phase 1 A Phase I open label study to assess the safety, tolerability, and efficacy of oral etoposide and oral topotecan administered in combination to patients with small-cell lung cancer who have not previously received chemotherapy (0 citation(s)) 104864/517 Phase 1 A Phase I study of oral topotecan as a radiosensitizing agent in patients with rectal cancer (0 citation(s)) 104864/535 Phase 2 A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer with Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer (0 citation(s)) 104864/552 Phase 2 A Phase II, Multicentre, Open Label Study of Oral Topotecan and Cisplatin in Ovarian Cancer Recurring ≥6 Months Following Initial Platinum-based Chemotherapy (1 citation(s)) 104864/557 Phase 2 A Phase II Trial Of Topotecan and Cisplatin In Patients With Metastatic Or Recurrent Squamous Cell Carcinoma Of The Cervix (0 citation(s)) 104864/612 Phase 2 A prospective, open label phase II study to evaluate the efficacy and safety of topotecan (Hycamtin) in combination with carboplatin as first-line chemotherapy in patients with ovarian cancer. (0 citation(s)) 104864/615 phase 2 An Open-Label, Multicenter, Randomized, Phase III Study Comparing Combination IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Advanced (IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) (0 citation(s)) 104864/623 Phase 2 An Open Label, Multicenter, Non-Comparative Phase II Study of Weekly Intravenous Vinorelbine and Topotecan in Chemotherapy-Nave Patients with Advanced Non-Small Cell Lung Cancer (4 citation(s)) 104864/627 Phase 2 An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients with Recurrent Platinum Sensitive Ovarian Cancer (0 citation(s)) 104864/692 Phase 1 A Study to Determine the Bioequivalence of an Oral Formulation of Topotecan Containing the Drug Substance Manufactured by New Process Relative to the Current Study Formulation of Topotecan in Patients with Advanced Solid Tumors (0 citation(s)) 104864/902 phase 2 An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 every 21 days) HYCAMTIN in Combination with Carboplatin (Day 1 every 21 days) as Second-Line Therapy in Subjects with Potentially Platinum-Sensitive Relapsed Ovarian Cancer (2 citation(s)) 104864/903 Phase 2 An open-label phase II study of weekly intravenous Hycamtin and carboplatin as first-line treatment of chemonaive subjects with Extensive Disease Small Cell lung Cancer (1 citation(s)) 104864-A/387 Phase 3 An Open-Label, Multicentre, Randomised, Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients with Pretreated Advanced Non Small Cell Lung Cancer (1 citation(s)) 104864-A/389 Phase 3 An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients with Extensive Disease-Small Cell Lung Cancer. (1 citation(s)) 104864-A/479 phase 3 An Open-Label, Multicentre, Randomised, Phase III Study Comparing Topotecan/Cisplatin and Topotecan/Etoposide versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients with Extensive Disease-Small Cell Lung Cancer (0 citation(s)) 114015 n\a Meta-analysis of efficacy of Topotecan and other treatments for recurrent carcinoma of the cervix (0 citation(s)) 114016 n\a Indirect Comparison of the efficacy between topotecan and other treatments for recurrent carcinoma of the cervix (0 citation(s)) HYT104152 phase 1 A Phase I Study to Characterize the Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30-Minute Intravenous Infusion in Patients with Cancer (1 citation(s)) HYT105962 phase 3 A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer (0 citation(s)) SKF104864/722 phase 1 A Phase I Study of Oral Topotecan in Subjects with Cancer and Impaired Renal Function (0 citation(s))
